Although numerous studies link elevated levels of AST/ALT ratio with decreased disease control and survival across different tumor types (10–14), the AST/ALT ratio’s impact in NSCLC patients receiving immunotherapy remains undefined. This evidence concerns the gene GPT and neoplasm.